Study Design and First Results of a Non-Interventional Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya®) in Multiple Sclerosis Patients in Germany (PANGAEA)

被引：0
|
作者：
Ziemssen, Tjalf [1 ]
van Lokven, Tom [2 ]
Kempke, Raimar [1 ]
Meergans, Matthias [2 ]
机构：
[1] Carl Gustav Carus Univ Hosp, Ctr Clin Neurosci, Dresden, Germany
[2] CNS Novartis Pharma GmbH, Clin Res, Nurnberg, Germany
来源：
NEUROLOGY | 2012年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P04131
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Study design and first results of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
    Ziemssen, T.
    van Lokven, T.
    Kempcke, R.
    Meergans, M.
    JOURNAL OF NEUROLOGY, 2012, 259 : S72 - S72
  • [2] Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)
    van Lokven, T.
    Kempcke, R.
    Ziemssen, T.
    Meergans, M.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S213 - S214
  • [3] Study design and first interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
    Ziemssen, T.
    Meergans, M.
    Vollmar, P.
    Kempcke, R.
    Tracik, F.
    van Lokven, T.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 222 - 223
  • [4] 18-Month Interim Results of a Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya®) in Multiple Sclerosis Patients in Germany (PANGAEA)
    Ziemssen, Tjalf
    Lorente, Maria Diaz
    Vollmar, Patrick
    Meergans, Matthias
    Tracik, Ferenc Mark
    Kempcke, Raimar
    van Lokven, Tom
    NEUROLOGY, 2013, 80
  • [5] 18-month interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
    Ziemssen, T.
    Vollmar, P.
    Diaz-Lorente, M.
    Fuchs, A.
    van Lokven, T.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 318 - 318
  • [6] Interim Results of the PANGAEA and PEARL Studies, Comparing Treatment Satisfaction and Pharmaco-Economic Data of Fingolimod (Gilenya®) and First-Line Therapies in Multiple Sclerosis Patients in Germany
    Ziemssen, Tjalf
    Vollmar, Patrick
    Meergans, Matthias
    Tracik, Ferenc Mark
    Lorente, Maria Diaz
    Neidhardt, Katja
    van Lokven, Tom
    NEUROLOGY, 2013, 80
  • [7] The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
    Ziemssen, Tjalf
    Kern, Raimar
    Cornelissen, Christian
    BMC NEUROLOGY, 2015, 15
  • [8] The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
    Tjalf Ziemssen
    Raimar Kern
    Christian Cornelissen
    BMC Neurology, 15
  • [9] First interim results on treatment satisfaction and pharmaco-economic data comparing Fingolimod and first-line therapies in multiple sclerosis patients in Germany (PANGAEA and PEARL)
    Ortler, Sonja
    Ziemssen, Tjalf
    Antonius, van Lokven
    Meergans, Matthias
    JOURNAL OF NEUROIMMUNOLOGY, 2012, 253 (1-2) : 31 - 32
  • [10] 5 years safety of fingolimod in real world: Results from PANGAEA, a non-interventional study of RRMS patients in Germany
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 197 - 197
12345